Ambah/PSI, the leading sterile injectable manufacturer in the Middle East and Africa (MEA) has announced its newest product Ambaprofen® the first Ibuprofen intravenous (IV) infusion (400mg/100ml) in the world.

Successfully registered through health authorities in Germany, Spain, Saudi Arabia, and many other countries, its patent has been granted by the European Patent Office (EPO patent no: 2636406); United States Patent and Trademark Office (uspto Patent No: US 9351926 B2) for its dosage form with the approval of the European Medicines Agency (EMA).

Ibuprofen is a well-established medicine and has over 40 years of safety and efficacy data as an oral treatment for mild to moderate pain and fever. Ambaprofen® (Ibuprofen 400mg/100ml IV Infusion), with its anal-gesic, antipyretic and anti-inflammatory properties is a safe option to treat pain and fever in hospitalized patients.

For any further details or to schedule a meeting at our CPhI Frankfurt stand, please contact ambaprofen@psi.com.sa